

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number  
**WO 2005/051390 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/4545**,  
31/46, C07D 211/38, 401/04, 451/04, A61P 25/04

(74) Agent: **HORGAN, James, Michael, Frederic**; Terlings  
Park, Eastwick Road, Harlow Essex CM20 2QR (GB).

(21) International Application Number:  
PCT/GB2004/004538

(22) International Filing Date: 27 October 2004 (27.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0325287.1 29 October 2003 (29.10.2003) GB

(71) Applicant (for all designated States except US): **MERCK  
SHARP & DOHME LIMITED** [GB/GB]; Hertford Road,  
Hoddesdon Hertfordshire EN11 9BU (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAYLISS, Tracy**  
[GB/GB]; Terlings Park, Eastwick Road, Harlow Es-  
sex CM20 2QR (GB). **BROWN, Rebecca, Elizabeth**  
[GB/GB]; Terlings Park, Eastwick Road, Harlow Essex  
CM20 2QR (GB). **BURKAMP, Frank** [DE/GB]; Terlings  
Park, Eastwick Road, Harlow Essex CM20 2QR (GB).  
**JONES, A., Brian** [GB/GB]; Terlings Park, Eastwick  
Road, Harlow Essex CM20 2QR (GB). **NEDUVELIL,**  
**Joseph, George** [GB/GB]; Terlings Park, Eastwick Road,  
Harlow Essex CM20 2QR (GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: E-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS  
WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN



(57) Abstract: Compounds of formula (I): wherein: A<sup>1</sup> is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S; A<sup>2</sup> is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S; L is a bond or C<sub>1-6</sub>alkylene; R<sup>1</sup> and R<sup>2</sup> independently chosen from hydrogen and C<sub>1-6</sub>alkyl or R<sup>1</sup> and R<sup>2</sup> may, together, form a methylene or ethylene bridge; W is halogen, C<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy or haloC<sub>1-6</sub>alkoxy; X is O, S or NR<sup>3</sup> or X, together with the atom to which it is attached, and Y, form an unsaturated five-membered ring together with A<sup>2</sup>; Y is a bond, C<sub>1-6</sub>alkylene, NH or NH(CH<sub>2</sub>)<sub>1-3</sub>; or a pharmaceutically acceptable salt thereof; other substituents are defined in claim 1; which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).